moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Other EventsItem 8.01. Other Events.
On November 1, 2017, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing that responses to U.S. Food and Drug Administration requests for additional information relating to the physician-sponsored Investigational New Drug application to study WP1066 as a potential treatment for brain tumors have been submitted. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description |
| 99.1 | Press release dated November 1, 2017 |
Moleculin Biotech, Inc. ExhibitEX-99.1 2 tv478275_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors HOUSTON – November 1,…To view the full exhibit click here
About moleculin biotech, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.
